NCCN Guidelines® Insights - Non-Hodgkin’s Lymphoma, 1.2013

These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Non-Hodgkin’s Lymphoma (NHL) and provide a discussion of the clinical evidence that support the updates. The updates discussed in this article feature recommendations for additional treatment options in patients with chronic lymphocytic leukemia and guidance surrounding the management of hepatitis virus reactivation/infections in high-risk patients with NHL undergoing antitumor therapy.

Target Audience

This activity has been designated to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Integrate into professional practice the updates to NCCN Guidelines for NHL
  • Describe the rationale behind the decision-making process for developing the NCCN Guidelines for NHL
Additional information
Supporters: 

Supported by educational grants from ARIAD Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals Inc.; CELGENE CORPORATION; Eisai Inc.; Endo Pharmaceuticals and HealthTronics; Genentech; Millennium: The Takeda Oncology Company; and Teva Pharmaceuticals

Course summary
Available credit: 
  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician
Course opens: 
03/15/2013
Course expires: 
03/15/2014
Cost:
$0.00

Available Credit

  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician

Price

Cost:
$0.00
Please login or register to take this course.